Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in Lennox-Gastaut Syndrome
NCT02224560Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of cannabidiol in Lennox-Gastaut syndrome (LGS), sponsored by Jazz Pharmaceuticals plc. Started Jun 2015; status: completed.
02
Drugs
cannabidiol
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT02224560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224560.